ADT	androgen deprivation therapy
AR	Androgen receptor
CTCs	circulating tumor cells
DCs	dendritic cells
DOT	duration of therapy
FGF	fibroblast growth factor
GM-CSF	granulocyte-macrophage colony-stimulating factor
mCRPC	metastatic castrate-resistant prostate cancer
PBMC	peripheral blood mononuclear cell
PD-L1	programmed cell death ligand 1
PMN-MDSCs	polymorphonuclear myeloid-derived suppressor cells
PSA	prostate-specific antigen